Non-Small-Cell Lung Cancer [Afatinib (Gilotrif) (Wave 2)] | LaunchTrends | US | 2014
LaunchTrends: Gilotrif is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Gilotrif (Boehringer Ingelheim’s afatinib).
LaunchTrends: Gilotrif measures the impact of this novel agent on the metastatic non-small-cell lung cancer (NSCLC) market following launch. The study surveyed medical oncologists from the United States and conducted qualitative interviews with physicians. These reports evaluate physicians’ current awareness and perception of Gilotrif relative to other currently available therapies for metastatic NSCLC, current and anticipated usage of Gilotrif, as well as promotional activity of Gilotrif.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
